Apollo Neuro Raises $15M in Series A Funding at Valuation Of Over $100M
Summary
Apollo Neuro, a Pittsburgh, PA-based maker of a scientifically validated wearable that improves the body’s resilience to stress, raised $15m in Series A funding at a valuation over $100m. Led by Dr. David Rabin, Psychiatrist, Neuroscientist, and Kathryn Fantauzzi, Co-Founder, and Co-Founder and CEO, Apollo leverages patented stress-relieving technology that actively helps the body recover quickly, enabling better sleep, relaxation, and focus. The wellness wearable is worn on either the wrist or ankle, and works by engaging with the sense of touch, delivering silent, soothing vibrations that help users feel safe and in control. Apollo Neuro’s scientifically validated technology trains the nervous system to bounce back from stress quickly. Currently the wearable is available for a one time purchase ($349) in the United States, Canada, Europe and Australia/New Zealand, and pairs with a mobile app.
Funding
Review available funding amount, funding date, investors, and linked company information related to Apollo Neuro Raises $15M in Series A Funding at Valuation Of Over $100M in the interactive ISVWorld profile.